Details of Disease

General Information of Disease (ID: DISUNQ2Q)

• Disease Name: Male breast carcinoma
• Synonyms: breast cancer in men; breast cancer, male; malignant neoplasm of male breast; neoplasm of male breast; carcinoma of Male breast; male breast carcinoma; Male breast cancer; carcinoma of male breast; carcinoma of the Male breast; Male breast carcinoma; male breast cancer
• Definition: A malignant neoplasm involving the male breast.
• Disease Hierarchy:
  DISH9F1N: Carcinoma
  DIS2UE88: Breast carcinoma
  DISUNQ2Q: Male breast carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005628
  MESH ID: D018567
  UMLS CUI: C0238033
  MedGen ID: 68650
  SNOMED CT ID: 372096000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Exemestane	DM9HPW3	Approved	Small molecular drug	[1]
Goserelin	DMAT8CG	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRIP1	TTZV7LJ	Disputed	Biomarker	[3]
CA12	TTSYM0R	Definitive	Altered Expression	[4]
HSD17B1	TTIWB6L	Definitive	Biomarker	[5]
PGR	TTUV8G9	Definitive	Altered Expression	[6]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SULT1A1	DEYWLRK	Strong	Genetic Variation	[7]

This Disease Is Related to 13 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANKRD30A	OTJXYAE5	Limited	Biomarker	[8]
DACH1	OTMKNAGG	Limited	Altered Expression	[9]
COX11	OT0N3WL9	Disputed	Genetic Variation	[10]
TOX3	OTC9NR4W	moderate	Genetic Variation	[11]
LYPD4	OTYNO8BS	Strong	Genetic Variation	[12]
RAD51B	OTCJVRMY	Strong	Biomarker	[13]
RNF4	OTCMXQRE	Strong	Biomarker	[14]
BCS1L	OT5PY5CY	Definitive	Biomarker	[15]
EIF5	OT79PQUN	Definitive	Biomarker	[16]
EMSY	OTBQ3KQE	Definitive	Biomarker	[17]
FANCL	OTJC7QPQ	Definitive	Genetic Variation	[18]
FANCM	OTNJG99Z	Definitive	Genetic Variation	[19]
TMSB4Y	OT1BMJ6B	Definitive	Biomarker	[20]

References

• [1] Exemestane FDA Label
• [2] Goserelin FDA Label
• [3] Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.Breast Cancer Res Treat. 2011 Apr;126(2):539-43. doi: 10.1007/s10549-010-1289-x. Epub 2010 Dec 17.
• [4] Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.PLoS One. 2013;8(1):e53353. doi: 10.1371/journal.pone.0053353. Epub 2013 Jan 4.
• [5] Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.Horm Cancer. 2013 Feb;4(1):1-11. doi: 10.1007/s12672-012-0126-6. Epub 2012 Oct 18.
• [6] Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.BMC Cancer. 2018 Dec 22;18(1):1282. doi: 10.1186/s12885-018-5216-6.
• [7] Association of SULT1A1 ArgHis polymorphism with male breast cancer risk: results from a multicenter study in Italy.Breast Cancer Res Treat. 2014 Dec;148(3):623-8. doi: 10.1007/s10549-014-3193-2. Epub 2014 Nov 11.
• [8] Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.J Cancer Res Clin Oncol. 2018 Feb;144(2):199-204. doi: 10.1007/s00432-017-2542-z. Epub 2017 Nov 7.
• [9] Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis.Clin Breast Cancer. 2018 Oct;18(5):e875-e882. doi: 10.1016/j.clbc.2018.01.011. Epub 2018 Feb 2.
• [10] Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men.PLoS Genet. 2011 Sep;7(9):e1002290. doi: 10.1371/journal.pgen.1002290. Epub 2011 Sep 15.
• [11] Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy.Breast Cancer Res Treat. 2013 Apr;138(3):861-8. doi: 10.1007/s10549-013-2459-4. Epub 2013 Mar 7.
• [12] Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.Eur J Cancer. 1999 Aug;35(8):1248-57. doi: 10.1016/s0959-8049(99)00135-5.
• [13] Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.Nat Genet. 2012 Nov;44(11):1182-4. doi: 10.1038/ng.2417. Epub 2012 Sep 23.
• [14] Coregulator small nuclear RING finger protein (SNURF) enhances Sp1- and steroid receptor-mediated transcription by different mechanisms.J Biol Chem. 2000 Jan 7;275(1):571-9. doi: 10.1074/jbc.275.1.571.
• [15] Breast conservation for male breast cancer: Case report of intraoperative radiation.Breast J. 2018 Jan;24(1):74-77. doi: 10.1111/tbj.12847. Epub 2017 Jun 8.
• [16] A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.Clin Cancer Res. 2017 May 15;23(10):2575-2583. doi: 10.1158/1078-0432.CCR-16-1952. Epub 2016 Dec 16.
• [17] EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.Breast Cancer Res Treat. 2016 Nov;160(1):181-186. doi: 10.1007/s10549-016-3976-8. Epub 2016 Sep 15.
• [18] Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.Breast Cancer Res Treat. 2018 May;169(1):105-113. doi: 10.1007/s10549-018-4661-x. Epub 2018 Jan 15.
• [19] A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.Breast. 2018 Apr;38:92-97. doi: 10.1016/j.breast.2017.12.013. Epub 2018 Jan 4.
• [20] TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.Oncotarget. 2015 Dec 29;6(42):44927-40. doi: 10.18632/oncotarget.6743.